Literature DB >> 2581493

Preleukemic myelodysplastic syndromes (MDS): pathogenetical considerations based on retrospective clinicomorphological sequential studies.

I Fohlmeister, R Fischer, H E Schaefer.   

Abstract

Analysis of myelodysplastic syndromes (MDS) in 77 patients terminating in "overt" leukemia revealed sequential changes of marrow morphology with respect to cellularity and involvement of lineages, indicating that different "forms" of MDS represent in reality different phases. Three main phases were observed, which occurred in the following non-reversible sequence: (a) hypocellular dysplasia (H), (b) hypercellular dysplasia with predominance of erythropoiesis (E), and (c) with predominance of myelo(mono)poiesis (MM). Published studies suggest that these phases represent different manifestation stages of the stem cell lesion leading to MDS. Manifestation may probably be promoted by factors causing marrow aplasia. Transition to "overt" leukemia in several cases occurred locally, not throughout the whole marrow. In some patients a mature myelo(mono)-cytic cell population showed the capacity for widespread tissue infiltration, characteristic of leukemic cells. This argues against the theory that "overt" leukemia is the result of continuous dedifferentiation in MDS, but favours the concept of multiple initiating "events" leading to evolution of a leukemic subclone within a myelodysplastic clone. A connection between leukemia differentiation and MDS phase, from which leukemia developed, was also observed indicating that the risk of different stem cell subpopulations to become the target of the leukemia initiating "event" varies during the course of myelodysplasia.

Entities:  

Mesh:

Year:  1985        PMID: 2581493

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.

Authors:  J Thiele; H Quitmann; S Wagner; R Fischer
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

2.  Hypocellular myelodysplastic syndromes: clinical and biological significance.

Authors:  Dragomir Marisavljevic; Vesna Cemerikic; Zoran Rolovic; Darinka Boskovic; Milica Colovic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  Recovery patterns of rat hemopoietic stem cells between pulse doses of 7,12-dimethylbenz(a)anthracene (DMBA) applied in a leukemogenic regimen.

Authors:  I Fohlmeister; O Hohentanner; A Porr
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 4.  Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Refractory myelodysplastic anaemias with hypocellular bone marrow.

Authors:  Y Yoshida; S Oguma; H Uchino; T Maekawa
Journal:  J Clin Pathol       Date:  1988-07       Impact factor: 3.411

6.  Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features.

Authors:  I Fohlmeister; R Fischer; B Mödder; M Rister; H E Schaefer
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

7.  Refractory cytopenias: clinical course according to bone marrow cytology and cellularity.

Authors:  A Riccardi; M Giordano; M Girino; M Cazzola; C M Montecucco; E Cassano; M Danova; G Ucci; A Castello; A Coci
Journal:  Blut       Date:  1987-03

8.  Diagnostic and prognostic value of DNA image cytometry in myelodysplasia.

Authors:  W Auffermann; I Fohlmeister; A Böcking
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

Review 9.  Human preleukaemia: do we have a model?

Authors:  A Jacobs
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

10.  Pancytopenic prodrome (pre-ALL) of acute lymphoblastic leukemia in adults: possible pathogenesis.

Authors:  S K Sohn; J S Suh; J Lee; K B Lee
Journal:  Korean J Intern Med       Date:  1998-02       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.